Biomea Fusion, Inc. (BMEA) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US09077A1060

Price
0.58 USD
Market cap
42.31 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Biomea Fusion, Inc. financials

Fiscal year2025
Operating income-83.51 m USD
EBIT-61.80 m USD
Net income-61.80 m USD
Diluted EPS – continuing operations-1.18 USD

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.